News

Most recently, Hiller has served as the CEO of venture-backed cardiovascular device start-up Heartscape Technologies. Prior to that he worked as the senior vice president at Millennium Pharmaceuticals.

BL-7040 has dual activity on both the nervous and immune systems which makes it suitable for treating both neurological diseases and immune system related conditions such as inflammatory

The milestone payment has been made following European Medicines Agency (EMA) acceptance of brentuximab vedotin marketing authorization application (MAA) as a treatment for relapsed or refractory Hodgkin lymphoma

As per the agreement, which was originally signed on 11 July 2008, Nycomed is responsible for the development, manufacturing and commercialization of veltuzumab in the subcutaneous formulation to

The MAA, submitted under the name ‘TESAMORELIN FERRER,’ is based on the positive results from two Phase 3 clinical trials, which enrolled more than 800 patients, and follows

to BBB is applying the G- Technology for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3 101. The company expects

Redwood’s technology was launched based on aldehyde tagging which functions as a chemical site on the surface of a protein that can be selectively modified through aldehyde specific

The patient recruitment has been started following the Argentinean approval which permits the company to recruit around eight patients with type 1 diabetes and severe hypoglycaemia. In the

In May this year Sanofi had signed a $613m licensing pact with Glenmark Pharmaceuticals Limited India (GPL) subsidiary Glenmark Pharmaceuticals SA (GPSA) to develop and commercialize a monoclonal